NCT02620163

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 381 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	telmisartan/amlodipine 40/5mg
DRUG	YH22162 40/5/12.5 mg
DRUG	telmisartan/amlodipine 80/5mg
DRUG	YH22162 80/5/25 mg
DRUG	telmisartan/amlodipine 40/5mg placebo
DRUG	YH22162 40/5/12.5 mg placebo
DRUG	telmisartan/amlodipine 80/5mg placebo
DRUG	YH22162 80/5/25 mg placebo

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2015-12-02
• Last updated: 2024-11-12

Locations

1 site across 1 country: South Korea